深圳迈瑞生物医疗电子股份有限公司 证券代码：300760 证券简称：迈瑞医疗 公告编号：2023-065 关于控股股东部分股份解除质押的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 深圳迈瑞生物医疗电子股份有限公司（以下简称"公司"）于近日接到公司控股股东 Magnifice（HK）Limited（以下简称"Magnifice（HK）"）的通知，获悉其将所持有的本公 司部分股份办理了解除质押业务，现将具体内容公告如下： 一、 股东股份解除质押的基本情况 | 股东名称 | 是否为 第一大 股东及 | 本次解除质 | 占其所 | 占公司总 股本比例 | 起始日 | | 解除日期 | | 质权人 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | 押股份数量 | 持股份 | | | | | | | | | 一致行 | （股） | 比例 | | | | | | | | | 动人 | | | | | | | | | | Magnifice （HK） | 是 | 8,300,0 ...

证券代码：300760 证券简称：迈瑞医疗 公告编号：2023-064 截至公告披露日，上述股东及其一致行动人所持质押股份情况如下： 深圳迈瑞生物医疗电子股份有限公司 关于控股股东部分股份质押的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 深圳迈瑞生物医疗电子股份有限公司（以下简称"公司"）于近日接到公司控股股东 Magnifice（HK）Limited（以下简称"Magnifice（HK）"）的通知，获悉其对所持有的公司 部分股份办理了质押业务，现将具体内容公告如下： 一、 股东股份质押的基本情况 | | 是否为 | | | | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | 控股股 东 或 | 第 | 本次质押 | 占其 | 占公 | 是否 | 是否 | | | | | | | | | | | 所持 | 司总 | | 为补 | 质押起 | | 质押到 | | 质押 | | 股东名称 | 一大股 | ...

证券代码：300760 证券简称：迈瑞医疗 公告编号：2023-063 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导 性陈述或重大遗漏。 一、交易概述 深圳迈瑞生物医疗电子股份有限公司（以下简称"公司"或"迈瑞医疗"）于2023年7月29 日批准通过与交易对手方签署《股权收购协议》和《股东协议》，为进一步加强海外供应链平 台建设，完善体外诊断产品研发，公司拟通过全资子公司迈瑞全球（香港）有限公司（英文名 为 MR Global (HK) Limited，以下简称为"香港全球"）及香港全球的全资子公司 Mindray Medical Netherlands B.V.（以下简称为"迈瑞荷兰"）以现金形式收购由Gorka Holding GmbH持 有的DiaSys Diagnostic Systems GmbH（以下简称"标的公司"）的75%股权（以下简称"本次交 易"）。股权交割完成后，标的公司及其下属子公司将纳入公司合并报表范围。 具体内容详见公司在创业板信息披露网站巨潮资讯网披露的《关于收购境外公司股权的公 告》（公告编号：2023-042）。 二、交易进展 2023年11月 ...

证券代码：300760 证券简称：迈瑞医疗 公告编号：2023-062 深圳迈瑞生物医疗电子股份有限公司 关于控股股东部分股份质押的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 深圳迈瑞生物医疗电子股份有限公司（以下简称"公司"）于近日接到公司控股股东 Magnifice（HK）Limited（以下简称"Magnifice（HK）"）的通知，获悉其对所持有的公司 部分股份办理了质押业务，现将具体内容公告如下： 一、 股东股份质押的基本情况 2．股东股份质押累计质押情况 截至公告披露日，上述股东及其一致行动人所持质押股份情况如下： | | | 持股 | | 本次质 押前质 | 本次质 押后质 | 占其所 | 占公 | 已质押 | 已质押股份情况 | 未质押 | 未质押股份情况 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 股东名称 | | 数量 | 持股 | 押股份 | 押股份 | 持股份 | 司总 | 股份限 | 占已 | | ...

证券代码：300760 证券简称：迈瑞医疗 公告编号：2023-061 深圳迈瑞生物医疗电子股份有限公司 2023年前三季度权益分派实施公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 深圳迈瑞生物医疗电子股份有限公司（下称"本公司"或"公司"）2023年前三季度 权益分派方案已获2023年11月13日召开的2023年第二次临时股东大会审议通过，现将权益 分派事宜公告如下： 一、股东大会审议通过利润分配方案等情况 1、公司2023年第二次临时股东大会审议通过的2023年前三季度利润分配方案为：以公 司2023年9月30日的总股本1,212,441,394股为基数，向全体股东每10股派发现金股利人民币 43.00元（含税），共计派发现金股利人民币5,213,497,994.20元（含税）。若公司股本总额在 权益分派实施前发生变化，公司将按照分配总额不变的原则对分配比例进行调整。 本次权益分派股权登记日为：2023年11月21日，除权除息日为：2023年11月22日 四、权益分派对象 本次分派对象为：截止2023年11月21日下午深圳证券交易所收市后，在中国证 ...

深圳迈瑞生物医疗电子股份有限公司 证券代码：300760 证券简称：迈瑞医疗 公告编号：2023-060 2023年第二次临时股东大会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导 性陈述或重大遗漏。 一、重要提示 1. 本次股东大会未出现否决议案的情形。 2. 本次股东大会不涉及变更以往股东大会决议。 二、会议召开情况 （一）会议召开时间 （1）现场会议：2023年11月13日15:00 （2）网络投票：通过深圳证券交易所交易系统进行网络投票的具体时间为：2023年11月13 日9:15-9:25、9:30-11:30，13:00-15:00；通过深圳证券交易所互联网投票系统进行网络投票的具 体时间为：2023年11月13日9:15至15:00期间的任意时间。 （二）现场会议召开地点：深圳市南山区高新技术产业园区科技南十二路迈瑞总部大厦会 议室 （三）会议召集人 深圳迈瑞生物医疗电子股份有限公司董事会 （四）投票方式 本次会议采取现场投票与网络投票相结合的方式召开。 本次股东大会通过深圳证券交易所交易系统和互联网投票系统向社会公众股股东提供网 络形式的投票平台。 （五 ...

上海 Shanghai·北京 Beijing·深圳 Shenzhen·广州 Guangzhou·香港 Hong Kong http://www.fangdalaw.com FANGDA PARTNERS 中国深圳市福田区中心四路 1 号 电子邮件 E-mail: email@fangdalaw.com 嘉里建设广场 T1 座 9 楼 电 话 Tel.: 86-755-8159-3999 邮政编码：518048 传 真 Fax: 86-755-8159-3900 9/F, Tower One, Kerry Plaza 1 Zhong Xin Si Road Futian District Shenzhen 518048, China 上海市方达（深圳）律师事务所 关于深圳迈瑞生物医疗电子股份有限公司 2023 年第二次临时股东大会的 法律意见书 本法律意见书依据《中华人民共和国公司法》《中华人民共和国证券法》《上 市公司股东大会规则》及其他相关中华人民共和国境内已公开颁布并生效的法律、 法规、规章及规范性文件（以下合称"中国法律法规"，仅为本法律意见书说明 之目的，不包括中国香港特别行政区、中国澳门特别行政区和 ...

Financial Performance - Total revenue for the first three quarters of 2023 reached 273.0 billion yuan, a year-on-year increase of 17.2% [2] - Q3 revenue was 88.3 billion yuan, up 11.2% year-on-year [3] - Net profit attributable to shareholders for the first three quarters was 98.3 billion yuan, a year-on-year increase of 21.4% [4] - Q3 net profit attributable to shareholders was 33.9 billion yuan, up 20.5% year-on-year [4] - Operating cash flow for the first three quarters was 77.7 billion yuan, a year-on-year increase of 15.3% [4] Regional Performance - Domestic market revenue for the first three quarters was 171.4 billion yuan, up 19.1% year-on-year, with Q3 growth slowing to 4.7% due to healthcare industry reforms [3] - International market revenue for the first three quarters was 101.6 billion yuan, up 14.2% year-on-year, with Q3 growth accelerating to 23.0% [3] - Developing countries achieved over 30% growth in Q3 [3] Product Line Performance - Life Information & Support product line grew 20.8% in the first three quarters, with minimally invasive surgery growing over 30% [3] - In-Vitro Diagnostics product line grew 18.5% in the first three quarters, with Q3 growth exceeding 20% [3] - Medical Imaging product line grew 9.1% in the first three quarters, with overseas ultrasound growing over 15% [4] R&D and Innovation - R&D investment in the first three quarters was 2.811 billion yuan, accounting for 10.3% of revenue, a year-on-year increase of 23.3% [5] - Launched new products including MT8000 fully automated laboratory system, high-sensitivity cardiac troponin I assay, and Resona R9 Platinum Edition ultrasound [5] Strategic Initiatives - Acquired 75% stake in DiaSys to strengthen overseas IVD supply chain platform [4] - Established over 50 ultrasound training centers globally, planning to benefit 10,000 medical students and doctors [5] - AED devices have successfully treated 200 cardiac arrest patients in public spaces in China as of September 30, 2023 [5] Market Expansion - Broke into over 200 new high-end customers in Life Information & Support product line overseas, with repeat purchases exceeding $70 million [9] - Expanded into nearly 350 key hospitals and laboratories in IVD product line overseas, including nearly 100 third-party chain laboratories [9] - Penetrated over 150 new high-end customers in Medical Imaging product line overseas [9] Future Outlook - Aims to enter global top 20 medical device companies by 2025 and top 10 in the long term [7] - Current market share in domestic IVD and minimally invasive surgery markets is only about 10% and 2% respectively, indicating significant growth potential [7] - Plans to expand into more market segments through both internal R&D and M&A [7]

Financial Performance - Revenue for Q3 2023 reached ¥8,828,024,468, an increase of 11.18% year-over-year[3] - Net profit attributable to shareholders was ¥3,392,313,091, reflecting a growth of 20.52% compared to the same period last year[3] - The net profit after deducting non-recurring gains and losses was ¥3,345,234,570, up by 21.35% year-over-year[3] - In the first three quarters of 2023, the company achieved operating revenue of CNY 27,303.80 million, an increase of 17.20% year-on-year[10] - The net profit attributable to shareholders of the listed company for the first three quarters was CNY 9,834.30 million, a year-on-year increase of 21.38%[11] - Total operating revenue for the current period reached ¥27,303,797,964, an increase of 17.5% compared to ¥23,295,830,669 in the previous period[19] - Net profit attributable to shareholders of the parent company was ¥9,834,303,940, representing a growth of 9.0% from ¥8,102,334,072 in the same period last year[20] - The total profit for the current period was ¥11,186,983,115, an increase of 21.0% from ¥9,228,271,866 in the previous period[20] Assets and Liabilities - Total assets at the end of Q3 2023 amounted to ¥49,992,718,322, representing a 6.95% increase from the end of the previous year[3] - Shareholders' equity attributable to the parent company was ¥36,821,362,106, a rise of 15.14% compared to the end of last year[3] - The company’s total liabilities decreased to CNY 13,171,356,216 from CNY 14,746,124,646, a reduction of about 10.7%[18] - The company’s total non-current assets reached CNY 21,732,026,324, an increase from CNY 16,139,431,165, representing a growth of approximately 34.5%[17] - The company reported total current liabilities of CNY 10,132,550,599, down from CNY 11,769,812,821, a decrease of about 14%[18] Cash Flow - The company reported a net cash flow from operating activities of ¥7,770,665,653, which increased by 15.27% year-over-year[3] - The net cash flow from operating activities for Q3 2023 was CNY 7,770,665,653, an increase from CNY 6,741,514,564 in Q3 2022, representing a growth of approximately 15.3%[23] - The total cash outflow from investing activities was CNY 5,909,588,098, compared to CNY 2,885,567,721 in the same period last year, indicating a significant increase of about 104.5%[23] - The net cash flow from financing activities was -CNY 5,593,159,035, slightly worse than -CNY 5,169,260,716 in Q3 2022, reflecting a decline of approximately 8.2%[23] - The total cash and cash equivalents at the end of Q3 2023 amounted to CNY 16,536,336,854, up from CNY 14,234,660,493 at the end of Q3 2022, marking an increase of about 16.1%[23] Research and Development - R&D investment for the first three quarters of 2023 was CNY 2,811 million, accounting for 10.3% of operating revenue, with a year-on-year growth of 23.3%[12] - The company has applied for a total of 9,697 patents, with 6,909 being invention patents as of September 30, 2023[12] Market Expansion and Product Development - The company launched several new products in Q3 2023, including the MT8000 fully automated laboratory line and high-sensitivity cardiac troponin I assay kit, among others[12] - International market growth in Q3 accelerated to over 20% quarter-on-quarter, with growth in developing countries reaching over 30%[10] - The company plans to continue expanding its market presence and investing in new product development to drive future growth[21] - The company plans to establish over 50 ultrasound training centers and schools globally, benefiting 10,000 medical students and doctors[13] Corporate Social Responsibility - The company donated 225 AED devices to partners and has successfully treated 200 cardiac arrest patients in public places with its AED equipment[13] Collaborations and Acquisitions - The company is collaborating with Tencent Health to promote digital upgrades in the medical device industry through cloud computing and AI technologies[13] - The company plans to acquire 75% equity of DiaSys Diagnostic Systems GmbH for cash through its wholly-owned subsidiary MR Global (HK) Limited and its subsidiary Mindray Medical Netherlands B.V.[15]

证券代码：300760 证券简称：迈瑞医疗 公告编号：2023-055 深圳迈瑞生物医疗电子股份有限公司 关于继续使用部分闲置募集资金进行现金管理的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 为持续提高深圳迈瑞生物医疗电子股份有限公司（以下简称"公司"）及子公司资金利 用效率，继续合理利用闲置募集资金，优化经济效益，公司于2023年10月26日召开第八届董 事会第四次会议及第八届监事会第四次会议，审议通过了《关于继续使用部分闲置募集资 金进行现金管理的议案》，同意在保证公司及子公司募集资金投资项目（以下简称"募投项 目"）资金需求的情况下，继续使用闲置募集资金进行现金管理，购买安全性高、流动性好 的存款类产品或保本型产品，包括但不限于大额存单、定期存款、结构性存款、通知存款、 协定存款、短期保本型产品等，使用期限自董事会审议通过之日起至2024年10月31日内有 效，有效期内业务实施总额不超过9.9亿元（含本数）。在上述额度及决议有效期内，业务 可循环滚动开展。具体内容公告如下： 一、募集资金基本情况 经中国证券监督管理委员会《关于核准深圳迈瑞生物医 ...